Rational Advisors LLC reduced its position in CVS Health Corp (NYSE:CVS) by 53.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 7,176 shares of the pharmacy operator’s stock after selling 8,319 shares during the period. Rational Advisors LLC’s holdings in CVS Health were worth $533,000 as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in CVS. M&G Investment Management Ltd. purchased a new position in CVS Health in the 4th quarter valued at approximately $79,201,000. Parnassus Investments CA lifted its position in shares of CVS Health by 14.1% during the third quarter. Parnassus Investments CA now owns 8,261,294 shares of the pharmacy operator’s stock worth $521,040,000 after acquiring an additional 1,020,904 shares in the last quarter. Haverford Trust Co. boosted its holdings in shares of CVS Health by 41.4% in the third quarter. Haverford Trust Co. now owns 2,231,574 shares of the pharmacy operator’s stock worth $140,745,000 after acquiring an additional 652,905 shares during the period. California Public Employees Retirement System boosted its holdings in shares of CVS Health by 24.3% in the third quarter. California Public Employees Retirement System now owns 3,056,916 shares of the pharmacy operator’s stock worth $192,800,000 after acquiring an additional 597,395 shares during the period. Finally, Coho Partners Ltd. grew its position in shares of CVS Health by 17.9% in the fourth quarter. Coho Partners Ltd. now owns 3,032,304 shares of the pharmacy operator’s stock valued at $225,270,000 after purchasing an additional 461,366 shares in the last quarter. Institutional investors and hedge funds own 76.69% of the company’s stock.
In related news, EVP Karen S. Lynch sold 80,143 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $75.00, for a total value of $6,010,725.00. Following the completion of the sale, the executive vice president now owns 41,831 shares in the company, valued at approximately $3,137,325. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Jonathan C. Roberts sold 57,563 shares of the business’s stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $72.63, for a total value of $4,180,800.69. Following the completion of the sale, the chief operating officer now owns 102,608 shares of the company’s stock, valued at approximately $7,452,419.04. The disclosure for this sale can be found here. Insiders sold 404,182 shares of company stock valued at $30,121,266 over the last quarter. 0.53% of the stock is owned by company insiders.
CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.73 EPS for the quarter, topping the Zacks’ consensus estimate of $1.68 by $0.05. The business had revenue of $66.89 billion during the quarter, compared to analysts’ expectations of $64.01 billion. CVS Health had a net margin of 1.83% and a return on equity of 15.45%. The business’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.14 EPS. As a group, equities research analysts predict that CVS Health Corp will post 7.03 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Thursday, January 23rd were issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.80%. The ex-dividend date of this dividend was Wednesday, January 22nd. CVS Health’s dividend payout ratio is currently 28.25%.
A number of analysts recently issued reports on CVS shares. Raymond James reiterated a “strong-buy” rating and set a $90.00 price objective (up from $80.00) on shares of CVS Health in a research note on Wednesday, December 4th. JPMorgan Chase & Co. raised their target price on CVS Health from $88.00 to $97.00 and gave the stock an “overweight” rating in a research note on Thursday, December 19th. Cfra lifted their target price on CVS Health from $85.00 to $86.00 and gave the company a “strong-buy” rating in a report on Wednesday. Robert W. Baird upped their price target on CVS Health from $70.00 to $73.00 and gave the company a “neutral” rating in a research report on Thursday. Finally, ValuEngine raised shares of CVS Health from a “strong sell” rating to a “sell” rating in a report on Friday, January 24th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. CVS Health presently has an average rating of “Buy” and an average price target of $78.48.
CVS Health Profile
CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.
See Also: Why does a company issue an IPO?
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.